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ABSTRACT
This cross-sectional study investigated the prevalence of goitre in Isfahan, a centrally-located city in Iran, 
15 years after the initiation of universal salt iodization. In total, 2,523 Isfahani adults (1,275 males, 1,248 
females) aged >20 years were selected by multi-stage cluster-sampling method. Goitre rate, serum thyroid-
stimulating hormone (TSH), thyroxine (T4), thyroid peroxidase antibody (TPOAb), thyroglobulin anti-
body (TgAb), and urinary iodine concentration (UIC) were measured and compared between the goitrous 
(n=478) and the non-goitrous (n=2,045) participants. The total goitre rate was 19% (n=478) of the 2,523 
adults. The rate of Grade I and II goitre was 12.4% (n=312) and 6.6% (n=166) respectively. The total goitre 
rate, Grade I and II goitre were more prevalent among women than among men. Hypothyroidism was 
observed in 6.4% (130/2,045) and 18.6% (89/478) of the non-goitrous and goitrous participants respec-
tively [odds ratio (OR)=3.6, 95% confidence interval (CI) 2.7-4.9, p=0.001]. Hyperthyroidism was present 
in 0.8% (17/2,045) and 5.2% (29/478) of the non-goitrous and goitrous adults respectively (OR=9.0, 95% 
CI 4.9-16.6, p=0.001). Hypothyroidism was more prevalent in Grade II than in Grade I goitre and among 
those without goitre (31.3%, 14.1%, and 6.4% respectively) (p=0.001). Positive TPOAb was observed in 
24% (n=50) of the non-goitrous and 33.5% (n=84) of the goitrous subjects (p=0.03). Positive TPOAb was 
observed in 24.6% (35 of 142) of the Grade I and 45% (49 of 109) of the Grade II goitrous adults (p=0.001). 
Positive TgAb was observed in 21.6% (n=45) of the non-goitrous and 35.9% (n=90) of the goitrous adults 
(p=0.001). Positive TgAb was observed in 30.3% (43 of 142) of the Grade I and 43.1% (47 of 109) of the 
Grade II goitrous adults (p=0.04). The median UIC was 18 µg/dL (range 1-80 µg/dL). It was 17.9 µg/dL and 
19 µg/dL in the non-goitrous and goitrous adults respectively. After 15 years of successful universal salt 
iodization in Isfahan, goitre is still endemic, which may be due to thyroid autoimmunity. However, other 
environmental or genetic factors may have a role. 
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INTRODUCTION
An estimated 750 million people worldwide are at a 
risk of iodine-deficiency disorders (IDDs), including 
endemic goitre, hypothyroidism, endemic cretin-
ism, and congenital anomalies (1,2). About 20 mil-
lion people in Iran suffered from iodine deficiency 
in 1989 (3) when the national salt-iodization pro-
gramme was initiated. Despite a comprehensive 
IDD-control programme, by 1994, less than 50% of 
rural households consumed iodized salt. Therefore, 
a law for the mandatory production of iodine salt 
for households was passed in 1994. Two years after 
the law was implemented, Azizi et al. evaluated the 
status of iodine intake in 26 provinces of Iran. They 
concluded that Iran had reached a sustainable con-
trol programme for iodine deficiency (4) as more 
than 90% of households were consuming iodized 
salt. However, goitre was endemic in all the prov-
inces, although the majority were Grade I goitre (4). 
The prevalence of goitre and the median urinary 
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centrally-located city in Iran, was reported to be 40-
50% and 13-20 µg/dL respectively in 1994 (4). 
The principal indicator of universal salt iodization 
for the control of IDDs is the median UIC, and the 
second indicator is thyroid size. It reflects by the 
prevalence of goitre (1) and the relationship be-
tween iodine intake and thyroid disease which is 
U-shaped. It means that both high and low iodine 
intake is associated with thyroid diseases, especially 
the presence of excessive iodine which accelerates 
thyroid autoimmunity disorders (5,6). 
In Tehran, Heydarian et al. investigated the rate of 
goitre, autoimmunity, and UIC before and after 
the salt-iodization programme. Results of the study 
showed that the prevalence of goitre decreased sig-
nificantly in 1999-2000, about 5-6 years after start-
ing the programme. They concluded that salt 
iodization resulted in adequate UIC, a decrease in 
serum thyroid-stimulating hormone (TSH) and 
subclinical hypothyroidism in males, and an in-
crease in thyroid autoantibodies without any sig-
nificant change in thyroid abnormalities (7).
The aim of our study was to assess the effects of 
iodine supplementation on the prevalence of goi-
tre, UIC, and thyroid autoantibodies among adults 
of Isfahan, Iran, with a population of 1,986,542 
(male 1,017,940, female 968,602) in 2006, 15 years 
after the salt-iodization programme. 
MATERIALS AND METHODS
Study population
In a cross-sectional study, 2,600 Isfahani adults 
were  selected  by  multi-stage  cluster-sampling 
method. At first stage, we randomly selected 40 
blocks on the city map. Then, we asked the post 
office to give us the addresses of all the homes in 
each block. We randomly selected 960 addresses 
from the list supplied by the post office (24 homes 
in each block). In this way, 2,600 adults were in-
vited. In total, 2,523 (97%) of the invited adults, 
aged 20-86 years, accepted our invitation and came 
for examination and testing from January to April 
2006. Their mean age was 39 [standard deviation 
(SD) 12.4] years. Of the 2,523 adults, 1,275 were 
males (50.5%), and 1,248 were females (49.5%). 
Trained personnel informed the people door to 
door and invited them to enroll into the study. Peo-
ple were asked to come to the Isfahan Endocrine 
and Metabolism Research Center (IEMRC), accord-
ing to a pre-planned appointment. Seven trained 
general practitioners filled out a questionnaire to 
provide some demographic data (sex, age, educa-
tion, employment status, and home address), past 
history of thyroid disorders, past or current usage 
of medications, including iodine supplementations 
(vitamins), iodine overload (amiodarone), or other 
drugs that could interfere with thyroid function 
(glucococorticoids). They checked the past medi-
cal documents of the participants and recorded the 
past medical history, including thyroid disorders, 
for each person. 
Those who had any history of thyroid disorders or 
abnormalities on physical examination or labora-
tory finding (TSH <0.3 mIU/L or TSH >4 mIU/L) 
were recalled for visit by the endocrinologist (AA). 
We sent a letter to each person. On this recall letter, 
the TSH concentration of the participants was sent 
to them by express mail to make sure that they can 
keep it as a medical document in their medical files 
to show to their own physician, if they would like. 
The interval between the first examination and the 
recalled invitation was about 2-3 weeks.  
Assessment of goitre
Thyroid size was graded according to the classifica-
tion of the World Health Organization to Grade 0 
(no palpable or visible), goitre I (palpable but not 
visible), and goitre II (visible) (2). The sum of Grade 
I and II was considered the total goitre rate (TGR) of 
the population studied.
Serum TSH, T4, T3, and thyroid autoantibody 
assays
Blood samples were obtained from all the partici-
pants and urine samples from about one-fourth 
(n=710) of them. Collected serum and urine sam-
ples were both frozen at-20 0C in the IEMRC labo-
ratory. 
In those people who had high TSH (>4 mIU/L) or 
low TSH (<0.3 mIU/L) concentration, the second 
blood sample was taken to measure TSH, T4, T3, 
and T3RU. Free T4 index (FT4I) was calculated by 
T4*T3RU. The second blood sample was taken at 
the same day from those who accepted our recall 
invitation and visited by the endocrinologist. It 
was about four weeks after the time in which the 
first blood sample had been taken.
TSH was measured by IRMA (immunoradiomet-
ric assay) (Kavoshyar kits, Tehran, Iran). Intra-
assay and inter-assay CV was 1.5% and 1.9% re-
spectively. The normal range for TSH was 0.3-4 
μU/mL. Aminorroaya A et al. Prevalence of goitre among adults in Iran
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Serum T4 was assayed by radioimmunoassay (RIA) 
(Kavoshyar kits, Tehran, Iran). Its intra- and inter-
assay CV was 4.7% and 4.9% respectively. The nor-
mal range for T4 concentration was 4.5-12 μg/dL. 
The normal range for T3 concentration was 80-190 
ng/dL. T3RU was assayed by RIA. Its intra- and in-
ter-assay CV was 3.6% and 4.4% respectively. The 
normal range for T3RU concentration was 25-35%. 
The normal range for FT4I according to our labora-
tory was 1.3-4.8.
TgAb and TPOAb were measured by Rapid ELISA 
(Genesis Diagnostic Co., London, UK). Intra-assay 
and inter-assay CV for TgAb was less than 12%, and 
for TPOAb, it was 7% and 5% respectively. Positive 
TgAb and TPOAb were considered to be concentra-
tions more than 100 IU/mL and 75 IU/mL, respec-
tively.
Measurement of urinary iodine 
UIC was measured by the digestion method based 
on a modification of Sandell-Kolthoff reaction. The 
intra-assay and inter-assay CV was 1.25% and 2.2% 
respectively (8). UIC of <10 µg/dL was considered 
iodine deficiency, UIC of >30 µg/dL iodine excess, 
and in between iodine sufficiency (1). 
Definitions: Thyroid function was defined as euthy-
roid (TSH level within the normal range, 0.3-4 
mIU/L), overt hypothyroidism (TSH >4 mIU/L 
and low FT4I levels), subclinical hypothyroidism 
(TSH level >4 mIU/L and normal serum FT4I lev-
els), overt hyperthyroidism (TSH level <0.3 mIU/L 
and high FT4I or high T3), and subclinical hyper-
thyroidism (TSH level <0.3 mIU/L and normal FT4I 
and normal T3) (8). 
Statistical analysis
Data were analyzed using the SPSS software (ver-
sion 13) and the Epi Info software (version 6.04). 
Variables with normal distribution, such as age, 
were expressed as mean (SD). To compare the mean 
age in different grades of goitre, analysis of variance 
(ANOVA) was used. To figure out where the differ-
ence existed when ANOVA showed that there was a 
difference between means in these groups, Scheffe 
test was applied. Those variables whose distribution 
was not normal were expressed as median (range). 
To compare the median of TSH, TPOAb, TgAb, and 
UIC, the presence of thyroid dysfunction (hypo-
thyroidism, hyperthyroidism), thyroid nodule, 
positive antithyroid antibodies (TPOAb, TgAb) be-
tween non-goitrous subjects and those with Grade 
I and Grade II goitre, chi-square test was used. The 
prevalence of goitre among different age-groups 
(≤30, 31-40, 41-50, and >50 years), sex-groups, and 
according to UIC and thyroid autoantibodies was 
compared by chi-square test. The p values of <0.05 
were considered significant.
Ethics
Our study was conducted in accordance with the 
ethical standards of the IEMRC Committee on 
Human Experimentation and with the Helsinki 
Declaration. The Regional Committee for Ethics of 
IEMRC and Isfahan University of Medical Sciences 
approved the study. Consents were obtained from 
participants before recruitment to the study.
RESULTS
The mean age of the 2,523 adults studied was 39 
(SD 12.4) years (range 20-86 years). Of them, 1,275 
were males, and 1249 were females. The mean age 
of the males was 41 (SD 12.7) years (range 20-80 
years), and the mean age of the females was 37 (SD 
12.4) years (range 20-86 years). 
The TGR was present in 19% (478/2,523) of the study 
subjects. The rate of Grade I and II goitre was 12.4% 
(312/2,523) and 6.6% (166/2,523) respectively. The 
prevalence of TGR, Grade I and II goitre was higher 
among women than among men (28.8%, 17.3%, 
and 11.5% for women vs 9.2%, 7.5%, and 1.7% 
for men (p<0.05). The prevalence of TGR, Grade I 
and II goitre among adults according to their age-
groups and gender is presented in Table 1. The rate 
of goitre decreased significantly (p<0.05) with the 
increase in age. Goitre was observed in 14.3% of 
the menopausal women (224/1,245) (7.6% Grade I, 
6.7% Grade II), which was lower compared to non-
menopausal women (324/1,006) [(14.3% vs 321%, 
odds ratio (OR)=0.35, 95% confidence interval (CI) 
0.24-0.52, p=0.001)].  
Characteristics of the non-goitrous and goitrous 
study population (Grade I and II and TGR) are re-
ported in Table 2.
Clinical nodule was observed in 2.5% of the adults. 
Thyroid nodule was observed in 9.4% of the goi-
trous patients [Grade I (5.1%) and II (17.5%) goi-
tre] versus 0.8% of the non-goitrous population 
(OR=12.4, 95% CI 7.0-21.9, p=0.001). It was ob-
served that 5.1% of the adults had Grade I goitre 
and 17.5% had Grade II goitre. Clinical nodule was 
more prevalent among the non-goitrous women 
than among men (1.2% vs 0.5%, OR=2.4, 95% CI 
0.9-6.5, p=0.007) but it was similar in the goitrous 
females (9.4%) and males (9.3%).Aminorroaya A et al. Prevalence of goitre among adults in Iran
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Thyroid function and goitre
Hypothyroidism was present in 6.4% (130/2,045) 
and 18.6% (89/478) of the non-goitrous and goi-
trous participants respectively (OR=3.6, 95% CI 2.7-
4.9, p=0.001). Whereas hyperthyroidism was ob-
served in 0.8% (17/2,045) and 5.2% (29/478) of the 
non-goitrous and goitrous participants respectively 
(OR=9.0, 95% CI 4.9-16.6, p=0.001). Hypothyroid-
ism was more prevalent in subjects with Grade II 
than in Grade I goitre and those without goitre 
(31.3%, 14.1%, and 6.4% respectively) (p=0.001).
Goitre according to TSH level
The prevalence of goitre (TGR), according to low, 
normal and high TSH levels, was 6.7% (n=21), 
77.2% (n=241), and 16.0% (n=50) respectively. TGR 
was more prevalent among subjects with higher 
than with low TSH level (p<0.05).
The prevalence of Grade I goitre, according to low, 
normal and high TSH levels, was 9.2% (n=44), 
70.9% (n=339), and 19.9% (n=95) respectively. The 
prevalence of Grade II goitre, according to low, nor-
mal and high TSH levels, was 13.9% (n=23), 59% 
(n=98), and 27.1% (n=45) respectively. 
Goitre and thyroid autoantibodies
Thyroid autoantibodies were measured in 459 
subjects (208 non-goitrous, 251 goitrous). Table 3 
shows the prevalence of positive antibodies among 
the goitrous and non-goitrous people in Isfahan. 
TPOAb and TgAb were positive in 29.2% (134/459) 
Table 2. Comparison of characteristics of goitrous (TGR*, Grade I and II) and non-goitrous Isfahani 
adults in 2006 [median (range)] or [mean (SD)]
Parameter Non-goitrous 
(n=2,045)
Grade I
(n=312)
Grade II
(n=166)
TGR
(n=478 )
p value
Age (years) 39.9 (12.6) 35.1 (10.8) 36.3 (10.6) 35.5 (10.8) 0.001
TSH (mU/L) 1.8 (0.04-127) 2 (0.03-100) 2.3 (0.02-83) 2 (0.02-100) 0.02
TPOAb (IU/mL)
6.8 (0.2-78)
 (n=208)
8.2 (0-3,000)
 (n=142)
42 (0-3,000)
 (n=109)
15.2 (0-3,000)
(n=251)
0.001
TgAb (IU/mL)
13.5 (0-9,000)
 (n=208)
24.5 (0-8,430)
 (n=142)
84 (0-9,000)
(n=109)
54 (0-9,000)
(n=251)
0.001
UIC (µg/dL)
17.9 (1-80)
(n=454)
17.7 (2.9-80)
(n=162)
20.6 (2-80)
(n=94)
19 (2-80)
(n=256)
0.1
*TGR: Total goitre rate (Grade I and II); SD=Standard deviation; TgAb=Thyroglobulin antibody; TPOAb=Thyroid 
peroxidase antibody; TSH=Thyroid-stimulating hormone; UIC=Urinary iodine concentration
Table 1. Prevalence of total goitre rate, Grade I and II goitre among adult Isfahani population: according 
to age-groups and gender in 2006
Age-group (years)
Grade I Grade II    TGR   
np/n % np/n % np/n %
Male
   ≤30
   31-40
   41-50
   >50
29/308
32/323
22/394
11/250
9.4
9.9
5.6
6.1
6/308
9/323
5/394
2/250
1.9
2.8
1.3
1.1
35/308
41/323
27/394
13/250
11.3
12.7
6.9
7.2
   Total 94/1,275   22/1,275  116/1,275
Female
   ≤30
   31-40
   41-50
   >50
97/448
55/319
49/273
13/208
21.7
17.2
17.9
8.0
52/448
50/319
26/273
12/208
11.6
15.7
9.5
7.4
149/448
105/319
75/273
25/208
33.3
32.9
27.4
15.4
   Total  214/1,249 140/1,249  354/1,248
All
   ≤30
   31-40
   41-50
   >50
126/756
87/642
71/667
24/458
16.7
13.5
10.6
5.2
58/756
59/642
31/667
14/458
7.7
9.2
4.6
3.1
184/756
146/642
102/667
38/458
24.4
22.7
15.2
8.3
   Total 308/2,523  162/2,523  470/2,523
np=Number of patients with goitre; n=Number of adults studied; TGR=Total goitre rateAminorroaya A et al. Prevalence of goitre among adults in Iran
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and 29.4% (135/459) of the adults. It was not higher 
in females (28.4%) than in males (31.1%) (p=0.32).
Positive TPOAb was present in 24% (n=50) of the 
non-goitrous and 33.5% (n=84) of goitrous subjects 
(p=0.03). Positive TPOAb was observed in 24.6% (35 
of 142) of the Grade I goitrous and 45% (49 of 109) 
of the Grade II goitrous participants (p=0.001).
TgAb was positive in 21.6% (n=45) of the non-goi-
trous and 35.9% (n=90) of the goitrous subjects 
(p=0.001). TgAb was positive in 30.3% (43/142) of 
people with Grade I goitre and 43.1% in those with 
(47 of 109) of Grade II goitre patients (p=0.04).
Goitre and urinary iodine concentration
UIC was measured in 710 participants (454 non-
goitrous, 256 goitrous). The median UIC was 18 
µg/dL (range 1-80 µg/dL) for the study participants. 
It was 17.9 µg/dL and 19 µg/dL in the non-goitrous 
and goitrous subjects respectively [not significant 
(NS)].
Iodine deficiency, sufficiency, and excess was 
observed in 152 (21.4%), 425 (59.9%), and 133 
(18.7%) of the adults respectively (p<0.01).
In the goitrous patients, 23% (n=59), 55.5% 
(n=149), and 21.5% (n=55) had iodine deficiency, 
sufficiency, and excess respectively (p=NS). There 
was no significant difference between the UIC and 
the prevalence of goitre (p=NS).
DISCUSSION
This study investigated the prevalence of goitre 
among the adults aged 20 years and older of Is-
fahan city, 15 years after the implementation of 
the national salt-iodization programme. Consider-
Table 3. Prevalence of positive thyroid autoantibodies among goitrous and non-goitrous people in Isfahan, 
2006
Goitre status
TPOAb or TgAb  TPOAb and TgAb Only TgAb Only TPOAb
No. % No. % No. % No. %
Non-goitrous 
(n=208)  68 32.7 27                 13 45 21.6 50 37.3
Goitrous (n=251) 
  Grade I
  Grade II
  TGR
58/142
68/109
126
40.8
62.4**
50.2†
20/142
28/109
  46
14.1
25.7**
18.3†
43/142
47/109
90
30.3
43.1**
35.8†
35/142
49/109
84
24.6
44.9**
33.5†
**p<0.05 Grade II vs non-goitrous in each antibody category with chi-square test; †p<0.05 TGR vs non-
goitrous in each antibody category with chi-square test; TgAb=Thyroglobulin antibody; *TGR: Total 
goitre rate (Grade I and II); TPOAb=Thyroid peroxidase antibody
ing that iodine deficiency was resolved in this city 
(median of UIC is 18 μg/dL), it is supposed that the 
prevalence of goitre must have been decreased.  Al-
though the rate of goitre decreased significantly, it 
is still endemic (19%). However, the prevalence of 
visible goitre was not high (6.6%) which is a good 
success in decreasing goitre.
Our findings corroborate with those of other studies 
in our country, which indicate that goitre persists 
in their study areas, despite adequate supplementa-
tion of iodine (7,9-10). In their study in Shahriar 
among 3,146 subjects aged 3-70 years, Azizi et al. re-
ported that 12 years after the initiation of universal 
salt iodization in Iran, its prevalence was still high 
(47%), although the rate of goitre decreased signifi-
cantly (9). Heydarian et al. reported that goitre was 
observed in 33% of women and 15.5% of men, 10 
years after the implementation of salt-iodization 
programme (10). In another study in Tehran, the 
rates of goitre, thyroid function, and autoantibod-
ies in adults aged ≥20 years were compared before 
1983-1984 and after 1999-2000 national salt iodiza-
tion. The prevalence of goitre was 25.2% (15.5% 
Grade I and 9.7% Grade II) in the study population 
with adequate iodine intake (7). It was 65.2% be-
fore the supplementation of iodine. 
Comparing our results with those of the above-
mentioned studies, the prevalence of goitre in Isfa-
han was lower. Our survey was done 15 years 
after iodine supplementation. Therefore, taking 
adequate iodine for a longer time is expected to de-
crease the size of goitre more efficiently. The longer 
duration of living in an iodine-sufficient state could 
explain the lower rate of goitre. However, it is still 
high. Either the time to decrease the size of goitre is 
not enough, or other factors could have a role. Aminorroaya A et al. Prevalence of goitre among adults in Iran
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A study in Laos to assess the impact of salt-iodiza-
tion programme found a higher median value of 
urinary iodine but almost a similar prevalence of 
goitre after the introduction of iodinated salt com-
pared to an earlier period (11). 
In Iran, salt iodization of 40 parts per million (PPM) 
has been done since 1994. The type of iodine has 
been used is potassium iodide. At regular intervals, 
adequacy of iodine supplementation has routinely 
been assessed in factories, shops, and households 
by the Ministry of Health. It has been adequate. For 
example, at factories and households, the mean 
(SD) iodine salt content has been about 33 (11) 
ppm and 32 (11) ppm respectively. However, ad-
equacy of salt iodization has been well-monitored 
(12). 
Recently, in their second national report on moni-
toring iodine-deficiency control, Azizi et al. have re-
ported a marked reduction in the rate of goitre (9.8%) 
and adequate UIC in school children (12). They con-
cluded that the prevalence of goitre decreased some 
years after the normalization of UIC, and for adults 
and older individuals, it may even take longer to 
achieve the effect of salt iodization (12). 
In our survey, the age of the adults ranged from 20 
to 80 years, and the salt-iodization programme has 
been in place for 15 years before the study was con-
ducted. It is expected that the full effect of iodine 
supplementation on goitre rate would be observed 
among those whose whole life has been spent in 
this period of time (children and adolescents) and 
not in older people whose established goitre is still   
persistent at least in some degrees. 
The prevalence of goitre in our country increased 
with age and was higher among women than 
among men as reported in other studies (7,10). In 
the HUNT study in Norway, which has been con-
sidered an iodine-sufficient area, the prevalence of 
goitre was 2.9% among women and 0.4% among 
men, and it was lower among younger groups than 
among older groups (13).
The median UIC in this study showed iodine suf-
ficiency (UIC=18 µg/dL), and the prevalence of 
TGR, Grade I and II goitre was not different among 
subgroups with iodine deficiency, sufficiency, and 
excess. Although iodine excess was observed in 
18.7% of the participants, it did not have any cor-
relation between goitre and iodine excess in the 
present study. It can be explained by the fact that 
urinary iodine excretion measured in one urine 
sample reflects the state of iodine intake just at that 
special day. However, data of other previous studies 
in Iran support our findings in being no correlation 
between UIC and goitre rate (7,10). 
The two studies in India conducted among ado-
lescents reported that there was no correlation be-
tween the iodine status and the goitre grades too 
(14,15).
Thus, our findings (Table 2 and 3) raise the issue 
with regard to whether the high prevalence of goi-
tre in this region is due to autoimmunity similar to 
what has already been reported by Heydarian et al. 
in Tehran (7). However, according to many studies, 
iodine is implicated in triggering or enhancing thy-
roid autoimmunity, at least in the formerly iodine-
deficient areas. This phenomenon has also been 
observed in other countries which were previously 
iodine-deficient where the transition to sufficient 
or excessive iodine intake was followed by an in-
crease in the incidence of thyroid autoimmunity 
(16,17). However, some other studies found no 
supporting evidence of autoimmunity induction 
after iodine administration to correct iodine defi-
ciency (18,19).
The presence of thyroid autoantibodies indicates 
an autoimmune thyroid disease component that 
may lead to the development of thyroid dysfunc-
tion. 
In our study, the prevalence of positive TPOAb and 
TgAb was higher among people with visible goitre 
than among those without goitre (Table 3).  It con-
firms the role of autoimmunity for Grade II goitre 
in the Isfahani adults.  
In a clinic-based study in Isfahan, 10-12 years 
after iodine repletion, the prevalence of posi-
tive thyroid autoantibodies was studied among 
women with and without thyroid diseases; the 
rate of positive TPOAb/TgAb in women with 
simple goitre was 48.9% and was much higher 
than the control group (35.6%) (20). Our popu-
lation-based study supports the findings of that 
clinic-based report. 
In our study, most goitrous adults were euthyroid. 
However, goitre was more prevalent among people 
with thyroid dysfunction. 
According to several studies, when iodine intake 
is changing from deficiency to sufficiency, there 
may be more cases of autoimmune hypothyroid-
ism whereas the increase in iodine intake may, over 
time, lead to hyperthyroidism (21).Aminorroaya A et al. Prevalence of goitre among adults in Iran
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In this study, thyroid nodule was more prevalent 
among the goitrous than among non-goitrous 
subjects, especially those with Grade II goitre. It in-
creased with age. In the study of Heydarian et al., it 
did not increase with age (10). 
Isfahan is an iodine-replete area. However, goitre 
is still endemic after 15 years of sufficient iodine 
intake. It seems that thyroid autoantibodies have 
a major role in the pathogenesis of goitre. Other 
probable environmental factors, such as selenium, 
iron and vitamin A deficiency, or thiocyanate over-
load, and genetic factors, should be investigated 
(22-24). Repetition of the study in the next decade 
is also suggested.
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